CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: hepatitis B surface antigen</title> <meta name="description" content="Search results for: hepatitis B surface antigen"> <meta name="keywords" content="hepatitis B surface antigen"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="hepatitis B surface antigen" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="hepatitis B surface antigen"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 6898</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: hepatitis B surface antigen</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6898</span> High Rate of Dual Carriage of Hepatitis B Surface and Envelope Antigen in Gombe in Infants and Young Children, North-East Nigeria: 2000-2015</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=E.%20Isaac">E. Isaac</a>, <a href="https://publications.waset.org/abstracts/search?q=I.%20Jalo"> I. Jalo</a>, <a href="https://publications.waset.org/abstracts/search?q=Y.%20Alkali"> Y. Alkali</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Ajani"> A. Ajani</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Rasaki"> A. Rasaki</a>, <a href="https://publications.waset.org/abstracts/search?q=Y.%20Jibrin"> Y. Jibrin</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Mustapha"> K. Mustapha</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Charanchi"> S. Charanchi</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Kudi"> A. Kudi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Danlami"> H. Danlami</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Hepatitis B infection is endemic in sub-Saharan Africa, where transmission predominantly occurs in infants and children by perinatal and horizontal routes. The risk of chronic infection peaks when infection is acquired early. Materials and Methods: Records of Hepatitis B surface and envelope antigen results in Federal Teaching Hospital, Gombe between May 2000 and May 2015 were retrieved and analyzed. Results: Paediatric outpatient visits and in-patient admissions were 64,193 accounting for 13% of total. Individuals tested for Hepatitis B surface antigenaemia were 23,866. Children aged 0-18 years constituted 11% (2,626). Among children tested, males accounted for 52.8% (1386/2626) and females 47.2% (1240/2626). Infants contributed 65 (2.3%); 1-4 year old children 309 (11.7%); 5-9 year old children 564 (21.4%) and adolescents 1717 (65.1%). HbSAg sero-positivity was 18% (496/2626) among children tested. The highest number of children tested per year was in 2009 (518) and 2014 (569) and the lowest, in the first study year (62). The highest sero-positivity rate was in 2010; 21.7% (54/255). Children aged 0-18years accounted for 10.5% (496/4720) of individuals with Hepatitis B surface antigenaemia. Sero-positivity was 3.1% (2/65); 12.9% (40/309); 18.1% (102/564); and 20.5% (352/1717) in infants, children ages 1-4years, 5-9years and adolescents respectively. 2.5% (1/40) and 4% (1/25) of male and female infants respectively had HbSAg. Among children aged 1-4years, 15.1% (30/198) of males and 9.0% (10/111) of females were seropositive; 14.8% (52/350) and 22% (50/224) of male and female 5-9year old children respectively has HbSAg. 14.3% (138/943) of adolescent females had Hepatitis B surface antigenaemia. Adolescent males demonstrated the highest sero-positivity rate 27.6% (214/774). 97.3% (483/496) of children who demonstrated Hepatitis B surface antigenaemia were tested for dual carriage with the e antigen. Males accounted for 296/483 (63.1%) and females 187/483 (36.9%). Infants constituted 0.97% (4/482); children aged 1-4years, 5-9years and adolescents were 6.8% (33/483); 20.9% (100/483) and 71.3% (342/483) respectively. 17.6% (85/483) of children tested had HBe antigenaemia. Of these, males accounted for 69.4% (59/85). 1.2% (1/85) were infants; 9.4% (8/85%) 1-4years; 22.3% (19/85) 5-9years and 68.2% (58/85) adolescents. 25% (1/4) infants; 24% (8/33) children aged 1-4 years; 19% (19/100) 5-9 year old children and 16.9% (58/342) adolescents had dual carriage. Infants and young children demonstrated the highest rate of dual carriage but were less likely to be tested for dual carriage 37/42 (88%) than their 5-9 year old 98% (100/102) and adolescent 342/352 (97%) counterparts. HB e antigen positivity rate was 45.4% (59/130) males and 36.0% (27/75) in females. Conclusion: Hepatitis B surface antigenaemia is high among adolescent males. Infants and young children who had HBSAg had the highest rate of envelope antigen carriage. Testing in pregnancy, vaccination programmes and prophylaxis need to be strengthened. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=children" title="children">children</a>, <a href="https://publications.waset.org/abstracts/search?q=dual%20carriage" title=" dual carriage"> dual carriage</a>, <a href="https://publications.waset.org/abstracts/search?q=Gombe" title=" Gombe"> Gombe</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B" title=" hepatitis B"> hepatitis B</a> </p> <a href="https://publications.waset.org/abstracts/43123/high-rate-of-dual-carriage-of-hepatitis-b-surface-and-envelope-antigen-in-gombe-in-infants-and-young-children-north-east-nigeria-2000-2015" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/43123.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">310</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6897</span> Optimization of Hepatitis B Surface Antigen Purifications to Improving the Production of Hepatitis B Vaccines on Pichia pastoris</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rizky%20Kusuma%20Cahyani">Rizky Kusuma Cahyani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis B is a liver inflammatory disease caused by hepatitis B virus (HBV). This infection can be prevented by vaccination which contains HBV surface protein (sHBsAg). However, vaccine supply is limited. Several attempts have been conducted to produce local sHBsAg. However, the purity degree and protein yield are still inadequate. Therefore optimization of HBsAg purification steps is required to obtain high yield with better purification fold. In this study, optimization of purification was done in 2 steps, precipitation using variation of NaCl concentration (0,3 M; 0,5 M; 0,7 M) and PEG (3%, 5%, 7%); ion exchange chromatography (IEC) using NaCl 300-500 mM elution buffer concentration.To determine HBsAg protein, bicinchoninic acid assay (BCA) and enzyme-linked immunosorbent assay (ELISA) was used in this study. Visualization of HBsAg protein was done by SDS-PAGE analysis. Based on quantitative analysis, optimal condition at precipitation step was given 0,3 M NaCl and PEG 3%, while in ion exchange chromatography step, the optimum condition when protein eluted with NaCl 500 mM. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis indicates that the presence of protein HBsAg with a molecular weight of 25 kDa (monomer) and 50 kDa (dimer). The optimum condition for purification of sHBsAg produced in Pichia pastoris gave a yield of 47% and purification fold 17x so that it would increase the production of hepatitis B vaccine to be more optimal. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20virus" title="hepatitis B virus">hepatitis B virus</a>, <a href="https://publications.waset.org/abstracts/search?q=HBsAg" title=" HBsAg"> HBsAg</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen" title=" hepatitis B surface antigen"> hepatitis B surface antigen</a>, <a href="https://publications.waset.org/abstracts/search?q=Pichia%20pastoris" title=" Pichia pastoris"> Pichia pastoris</a>, <a href="https://publications.waset.org/abstracts/search?q=purification" title=" purification"> purification</a> </p> <a href="https://publications.waset.org/abstracts/91001/optimization-of-hepatitis-b-surface-antigen-purifications-to-improving-the-production-of-hepatitis-b-vaccines-on-pichia-pastoris" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/91001.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">151</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6896</span> Predictive Value of Hepatitis B Core-Related Antigen (HBcrAg) during Natural History of Hepatitis B Virus Infection</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yanhua%20Zhao">Yanhua Zhao</a>, <a href="https://publications.waset.org/abstracts/search?q=Yu%20Gou"> Yu Gou</a>, <a href="https://publications.waset.org/abstracts/search?q=Shu%20Feng"> Shu Feng</a>, <a href="https://publications.waset.org/abstracts/search?q=Dongdong%20Li"> Dongdong Li</a>, <a href="https://publications.waset.org/abstracts/search?q=Chuanmin%20Tao"> Chuanmin Tao</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The natural history of HBV infection could experience immune tolerant (IT), immune clearance (IC), HBeAg-negative inactive/quienscent carrier (ENQ), and HBeAg-negative hepatitis (ENH). As current biomarkers for discriminating these four phases have some weaknesses, additional serological indicators are needed. Hepatits B core-related antigen (HBcrAg) encoded with precore/core gene contains denatured HBeAg, HBV core antigen (HBcAg) and a 22KDa precore protein (p22cr), which was demonstrated to have a close association with natural history of hepatitis B infection, but no specific cutoff values and diagnostic parameters to evaluate the diagnostic efficacy. This study aimed to clarify the distribution of HBcrAg levels and evaluate its diagnostic performance during the natural history of infection from a Western Chinese perspective. 294 samples collected from treatment-naïve chronic hepatitis B (CHB) patients in different phases (IT=64; IC=72; ENQ=100, and ENH=58). We detected the HBcrAg values and analyzed the relationship between HBcrAg and HBV DNA. HBsAg and other clinical parameters were quantitatively tested. HBcrAg levels of four phases were 9.30 log U/mL, 8.80 log U/mL, 3.00 log U/mL, and 5.10 logU/mL, respectively (p < 0.0001). Receiver operating characteristic curve analysis demonstrated that the area under curves (AUCs) of HBcrAg and quantitative HBsAg at cutoff values of 9.25 log U/mL and 4.355 log IU/mL for distinguishing IT from IC phases were 0.704 and 0.694, with sensitivity 76.39% and 59.72%, specificity 53.13% and 79.69%, respectively. AUCs of HBcrAg and quantitative HBsAg at cutoff values of 4.15 log U/mlmL and 2.395 log IU/mlmL for discriminating between ENQ and ENH phases were 0.931 and 0.653, with sensitivity 87.93% and 84%, specificity 91.38% and 39%, respectively. Therefore, HBcrAg levels varied significantly among four natural phases of HBV infection. It had higher predictive performance than quantitative HBsAg for distinguishing between ENQ-patients and ENH-patients and similar performance with HBsAg for the discrimination between IT and IC phases, which indicated that HBcrAg could be a potential serological marker for CHB. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B" title="chronic hepatitis B">chronic hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20core-related%20antigen" title=" hepatitis B core-related antigen"> hepatitis B core-related antigen</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigens" title=" hepatitis B surface antigens"> hepatitis B surface antigens</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20virus" title=" hepatitis B virus"> hepatitis B virus</a> </p> <a href="https://publications.waset.org/abstracts/68938/predictive-value-of-hepatitis-b-core-related-antigen-hbcrag-during-natural-history-of-hepatitis-b-virus-infection" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/68938.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">417</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6895</span> The Prevalence of Blood-Borne Viral Infections among Autopsy Cases in Jordan</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Emad%20Al-Abdallat">Emad Al-Abdallat</a>, <a href="https://publications.waset.org/abstracts/search?q=Faris%20G.%20Bakri"> Faris G. Bakri</a>, <a href="https://publications.waset.org/abstracts/search?q=Azmi%20Mahafza"> Azmi Mahafza</a>, <a href="https://publications.waset.org/abstracts/search?q=Rayyan%20Al%20Ali"> Rayyan Al Ali</a>, <a href="https://publications.waset.org/abstracts/search?q=Nidaa%20Ababneh"> Nidaa Ababneh</a>, <a href="https://publications.waset.org/abstracts/search?q=Ahmed%20Idhair"> Ahmed Idhair </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Morgues are high-risk areas for the spread of infection from the cadavers to the staff during the postmortem examination. Infection can spread from corpses to workers by the airborne route, by direct contact, or from needle and sharp object injuries. Objective: Knowledge about the prevalence of these infections among autopsies is prudent to appreciate any risk of transmission and to further enforce safety measures. Method: A total of 242 autopsies were tested. Age ranged from 3 days to 94 years (median 75.5 years, mean 45.3 (21.9 ± SD)). There were 172 (71%) males. Results: The cause of death was considered natural in 137 (56.6%) cases, accidental in 89 (36.8%), homicidal in 9 (3.7%), suicidal in 4 (1.7%), and unknown in 3 (1.2%). Hepatitis B surface antigen was positive in 5 (2.1%) cases. Hepatitis C virus antibody was detected in 5 (2.1%) cases and the hepatitis C virus polymerase chain reaction was positive in 2 of them (0.8%). HIV antibody was not detected in any of the cases. Conclusions: Autopsies can be associated with exposure to blood borne viruses. Autopsies performed during the study period were tested for hepatitis B surface antigen, hepatitis C virus antibody, and human immunodeficiency virus antibody. Positive tests were subsequently confirmed by polymerase chain reaction. There is low prevalence of infections with these viruses in our autopsy cases. However, the risk of transmission remains a threat. Healthcare workers in the forensic departments should adhere to standard precautions. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=autopsy" title="autopsy">autopsy</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20virus" title=" hepatitis B virus"> hepatitis B virus</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20C%20virus" title=" hepatitis C virus"> hepatitis C virus</a>, <a href="https://publications.waset.org/abstracts/search?q=human%20immunodeficiency%20virus" title=" human immunodeficiency virus"> human immunodeficiency virus</a>, <a href="https://publications.waset.org/abstracts/search?q=Jordan" title=" Jordan"> Jordan</a> </p> <a href="https://publications.waset.org/abstracts/52932/the-prevalence-of-blood-borne-viral-infections-among-autopsy-cases-in-jordan" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/52932.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">379</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6894</span> Sero-Prevalence of Hepatitis B Surface Antigen and Associated Factors among Pregnant Mothers Attending Antenatal Care Service, Mekelle, Ethiopia: Evidence from Institutional Based Quantitative Cross-Sectional Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Semaw%20A.">Semaw A.</a>, <a href="https://publications.waset.org/abstracts/search?q=Awet%20H."> Awet H.</a>, <a href="https://publications.waset.org/abstracts/search?q=Yohannes%20M."> Yohannes M.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Hepatitis B Virus (HBV) is a major global public health problem. Individuals living in Sub-Sahara Africa have 60% lifetime risk of acquiring HBV infection. Evidences showed that 80-90% of those born from infected mothers developed chronic HBV. Perinatal HBV transmission is a major determinant of HBV carrier status, its chronic squeal and maintains HBV transmission across generations. Method: Institution based cross-sectional study was conducted among 406 pregnant mothers attending Antenatal clinics at Mekelle and Ayder referral hospital from January 30 to April 1/2014. Epidata version 3.1 was used for data entry and SPSS version 21 statistical software was used for data cleaning, management and finally determine associated factors of hepatitis B surface antigen adjusting important confounders using multivariable logistic regression analysis at 5% level of significance. Result: The overall prevalence of hepatitis B surface antigen among pregnant women was 33 (8.1%). The socio-demographic characteristic of the study population showed that there is high positivity among secondary school 189 (46.6%). In the multivariable logistic regression analysis, history of a contact with individuals who had history of hepatitis B infection or jaundice and lifetime number of multiple sexual partners were found to be significantly associated with HBsAg positivity at AOR = 3.73 95%C.I (1.373-10.182) and AOR = 2.57 95%C.I (1.173-5.654), respectively. Moreover, Human Immunodeficiency Virus (HIV) and HBV confection rate was found 3.6%. Conclusion: This study has shown that HBV prevalence in pregnant women is highly prevalent (8.1%) in the study area. Contact with individuals who had a history of hepatitis or have jaundice and report of multiple lifetime sexual partnership were associated with hepatitis B infection. Education about HBV transmission and prevention as well as screening all pregnant mothers shall be sought to reduce the serious public health crisis of HBV. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HBsAg" title="HBsAg">HBsAg</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B" title=" hepatitis B"> hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=pregnant%20women" title=" pregnant women"> pregnant women</a>, <a href="https://publications.waset.org/abstracts/search?q=prevalence" title=" prevalence"> prevalence</a> </p> <a href="https://publications.waset.org/abstracts/34139/sero-prevalence-of-hepatitis-b-surface-antigen-and-associated-factors-among-pregnant-mothers-attending-antenatal-care-service-mekelle-ethiopia-evidence-from-institutional-based-quantitative-cross-sectional-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34139.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">340</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6893</span> Dual Carriage of Hepatitis B Surface and Envelope Antigen in Adults in the Poorest Region of Nigeria: 2000-2015</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=E.%20Isaac">E. Isaac</a>, <a href="https://publications.waset.org/abstracts/search?q=I.%20Jalo"> I. Jalo</a>, <a href="https://publications.waset.org/abstracts/search?q=Y.%20Alkali"> Y. Alkali</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Ajani"> A. Ajani</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Rasaki"> A. Rasaki</a>, <a href="https://publications.waset.org/abstracts/search?q=Y.%20Jibrin"> Y. Jibrin</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Mustapha"> K. Mustapha</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Ayuba"> A. Ayuba</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Charanchi"> S. Charanchi</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Danlami"> H. Danlami</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Hepatitis B infection continues to be a serious global health problem with about 2 billion people infected worldwide, many of these in sub-Saharan Africa. Nigeria is one of the countries with the highest incidence, with a prevalence of 10-15%. Methods: Records of Hepatitis B surface and envelope antigen test results in adults in Federal Teaching Hospital, Gombe between May 2000 and May 2015 were retrieved and analyzed. Findings: Adult out-patient consultations and in-patient admissions were 343,083 and 67,761 respectively, accounting for 87% of total. Hepatitis B surface antigenaemia was tested for in 23,888 adults and children. 88.9% (21240) were adults. Males constituted 56% (11902/21240) and females 44% (9211/21240). 5104 (24.0%) of tested individuals were 19-25years; 12,039 (56.7%) 26-45years; 21119 (9.0%) 46-55years; 2.8% (590/21240) and 766 (3.6%) >65years. Among adult males, 17% (2133/11902) was contributed by ages 19-25. 58% (7017/11902), 11.9% (1421/11902), 6.4% (765/11902) and 4.7% (563/11902) of males were 26-45 years old, 46-55 years old and 56-65 years and >65year old respectively. Adults aged 19-25years, 26-45 years, 46-55years, 56-65 and > 65years each constituted 32% (2966/9211); 54.4% (5009/9211); 7.4% (684/9211), 3.8% (350/9211) and 2.2% (201/9211) of females respectively. 16.2% (3431/21,240) demonstrated Hepatitis B surface antigenaemia. The sero-positivity rate was 16.9% (865//5104) between 19-25years, 21.2% (2559/12,039) among 26-45year old individuals. 17.9% (377/2111); 14.1% (83/590) and 7.3% (56/766) of 46-55year old, 56-65year old and >65year old individuals screened were seropositive. The highest sero-positivity rate was found in male young adults aged 19-25years 27.9% (398/1426) and lowest in elderly males 7.4% (28/377). HBe antigen testing rate among HbSAg seropositive individuals was 97.3% (3338/3431). Males constituted 59.7% (1992/3338) and females 40.3% (1345/3338). 25.3% (844/3338) were aged 19-25years; 61.1% (2039/3338) 26-45years; 10.2% (340/3338) 46-55years; 2.7% (90/3338) 56-65years and 0.7% >65years old. HB e antigenaemia was positive in 8.2% (275/3338) of those tested. 41% (113/275); 50.2% (138/275); 5.4% (15/275); 1.8% (5/275) and 1.1 (3/275) of HB e sero-positivity was among age groups 19-25, 26-45, 46-55, 56-65 and > 65year old individuals. Dual sero-positivity rate was highest 13% (113/844) in young adults 19-25years and lowest between 46-55years; 15/340 (4.4%). 4.2% (15/360); 13.5% (69/512); 6.7% (90/1348); 4.6% (10/214); 5% (2/40) and 6.7% (1/15) of males aged 19-25; 26-45; 46-55; 56-65; and >65years had HB e antigenaemia respectively. Among females - 27/293 (9.2%) aged 19-25; 26/500 (5.2%) 26-45; 2/84 (2.4%) 46-55; 1/12 (8.3%) 56-65 and 1/9(11.1%) >65years had dual antigenaemia. In women of childbearing age, 6.9% (53/793) had a dual carriage. Conclusion: Dual hepatitis B surface and envelope antigenaemia are highest in young adult males. This will have significant implications for the development of chronic liver disease and hepatocellular carcinoma. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=adult" title="adult">adult</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20B" title=" Hepatitis B"> Hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=Nigeria" title=" Nigeria"> Nigeria</a>, <a href="https://publications.waset.org/abstracts/search?q=dual%20carriage" title=" dual carriage"> dual carriage</a> </p> <a href="https://publications.waset.org/abstracts/43126/dual-carriage-of-hepatitis-b-surface-and-envelope-antigen-in-adults-in-the-poorest-region-of-nigeria-2000-2015" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/43126.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">260</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6892</span> Histochemical Localization of Hepatitis B Surface Antigen in Hepatocellular Carcinoma: An Evaluation of Two Staining Techniques in a Tertiary Hospital in Calabar, Nigeria</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Imeobong%20Joseph%20Inyang">Imeobong Joseph Inyang</a>, <a href="https://publications.waset.org/abstracts/search?q=Aniekan-Augusta%20Okon%20Eyo"> Aniekan-Augusta Okon Eyo</a>, <a href="https://publications.waset.org/abstracts/search?q=Abel%20William%20Essien"> Abel William Essien</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis B virus (HBV) is one of the known human carcinogens. The presence of HBsAg in liver tissues indicates active viral replication. More than 85% of Hepatocellular Carcinoma (HCC) cases occur in countries with increased rates of chronic HBV infection. An evaluation study to determine the relationship between positivity for HBsAg and development of HCC and its distribution between age and gender of subjects was done. Shikata Orcein and Haematoxylin and Eosin (H&E) staining techniques were performed on liver sections. A total of 50 liver tissue specimens comprising 38 biopsy and 12 post-mortem specimens were processed. Thirty-five of the 50 specimens were positive for HBsAg with Orcein stain whereas only 16 were positive with H&E stain, and these were also positive with Orcein stain, giving an HBsAg prevalence of 70.0% (35/50). The prevalence of HCC in the study was 56.0% (28/50), of which 21 (75.0%) cases were positive for HBsAg, 18 (64.3%) were males while 10 (35.7%) were females distributed within the age range of 20-70 years. The highest number of HBsAg positive HCC cases, 7/21 (33.3%) occurred in the age group 40-49 years. There was no relationship in the pattern of distribution of HCC between age and gender using the Pearson correlation coefficient (r = 0.0474; P < 0.05). HBV infection predisposed to HCC. Orcein technique was more specific and is therefore recommended for screening of liver tissues where facilities for immunohistochemistry are inaccessible. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20B.%20surface%20antigen" title="Hepatitis B. surface antigen">Hepatitis B. surface antigen</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatocellular%20carcinoma" title=" hepatocellular carcinoma"> hepatocellular carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=orcein" title=" orcein"> orcein</a>, <a href="https://publications.waset.org/abstracts/search?q=pathology" title=" pathology"> pathology</a> </p> <a href="https://publications.waset.org/abstracts/6196/histochemical-localization-of-hepatitis-b-surface-antigen-in-hepatocellular-carcinoma-an-evaluation-of-two-staining-techniques-in-a-tertiary-hospital-in-calabar-nigeria" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/6196.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">313</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6891</span> Quantitative Analysis of Carcinoembryonic Antigen (CEA) Using Micromechanical Piezoresistive Cantilever </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Meisam%20Omidi">Meisam Omidi</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Mirijalili"> M. Mirijalili</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammadmehdi%20Choolaei"> Mohammadmehdi Choolaei</a>, <a href="https://publications.waset.org/abstracts/search?q=Z.%20Sharifi"> Z. Sharifi</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Haghiralsadat"> F. Haghiralsadat</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Yazdian"> F. Yazdian </a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this work, we have used arrays of micromechanical piezoresistive cantilever with different geometries to detect carcinoembryonic antigen (CEA), which is known as an important biomarker associated with various cancers such as the colorectal, lung, breast, pancreatic, and bladder cancer. The sensing principle is based on the surface stress changes induced by antigen–antibody interaction on the microcantilevers surfaces. Different concentrations of CEA in a human serum albumin (HSA) solution were detected as a function of the deflection of the beams. According to the experiments, it was revealed that microcantilevers have surface stress sensitivities in the order of 8 (mJ/m). This matter allows them to detect CEA concentrations as low as 3 ng/mL or 18 pM. This indicates the fact that the self-sensing microcantilever approach is beneficial for pathological tests. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=micromechanical%20biosensors" title="micromechanical biosensors">micromechanical biosensors</a>, <a href="https://publications.waset.org/abstracts/search?q=carcinoembryonic%20antigen%20%28CEA%29" title=" carcinoembryonic antigen (CEA)"> carcinoembryonic antigen (CEA)</a>, <a href="https://publications.waset.org/abstracts/search?q=surface%20stress" title=" surface stress"> surface stress</a> </p> <a href="https://publications.waset.org/abstracts/1739/quantitative-analysis-of-carcinoembryonic-antigen-cea-using-micromechanical-piezoresistive-cantilever" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/1739.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">472</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6890</span> Investigation of Suspected Viral Hepatitis Outbreaks in North India</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mini%20P.%20Singh">Mini P. Singh</a>, <a href="https://publications.waset.org/abstracts/search?q=Manasi%20Majumdar"> Manasi Majumdar</a>, <a href="https://publications.waset.org/abstracts/search?q=Kapil%20Goyal"> Kapil Goyal</a>, <a href="https://publications.waset.org/abstracts/search?q=Pvm%20Lakshmi"> Pvm Lakshmi</a>, <a href="https://publications.waset.org/abstracts/search?q=Deepak%20Bhatia"> Deepak Bhatia</a>, <a href="https://publications.waset.org/abstracts/search?q=Radha%20Kanta%20Ratho"> Radha Kanta Ratho</a> </p> <p class="card-text"><strong>Abstract:</strong></p> India is endemic for Hepatitis E virus and frequent water borne outbreaks are reported. The conventional diagnosis rests on the detection of serum anti-HEV IgM antibodies which may take 7-10 days to develop. Early diagnosis in such a situation is desirable for the initiation of prompt control measures. The present study compared three diagnostic methods in 60 samples collected during two suspected HEV outbreaks in the vicinity of Chandigarh, India. The anti-HEV IgM, HEV antigen and HEV-RNA could be detected in serum samples of 52 (86.66%), 16 (26.66%) and 18 (30%) patients respectively. The suitability of saliva samples for antibody detection was also evaluated in 21 paired serum- saliva samples. A total of 15 serum samples showed the presence of anti HEV IgM antibodies, out of which 10 (10/15; 66.6%) were also positive for these antibodies in saliva samples (χ2 = 7.636, p < 0.0057), thus showing a concordance of 76.91%. The positivity of reverse transcriptase PCR and HEV antigen detection was 100% within one week of illness which declined to 5-10% thereafter. The outbreak was attributed to HEV Genotype 1, Subtype 1a and the clinical and environmental strains clustered together. HEV antigen and RNA were found to be an early diagnostic marker with 96.66% concordance. The results indicate that the saliva samples can be used as an alternative to serum samples in an outbreak situation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HEV-antigen" title="HEV-antigen">HEV-antigen</a>, <a href="https://publications.waset.org/abstracts/search?q=outbreak" title=" outbreak"> outbreak</a>, <a href="https://publications.waset.org/abstracts/search?q=phylogenetic%20analysis" title=" phylogenetic analysis"> phylogenetic analysis</a>, <a href="https://publications.waset.org/abstracts/search?q=saliva" title=" saliva"> saliva</a> </p> <a href="https://publications.waset.org/abstracts/39350/investigation-of-suspected-viral-hepatitis-outbreaks-in-north-india" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/39350.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">420</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6889</span> Seroprevalence of Hepatitis B and C among Healthcare Workers in Dutse Metropolis, Jigawa State, Nigeria</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=N.%20M.%20Sani">N. M. Sani</a>, <a href="https://publications.waset.org/abstracts/search?q=I.%20Bitrus"> I. Bitrus</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20M.%20Sarki"> A. M. Sarki</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20S.%20Mujahid"> N. S. Mujahid</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis is one of the neglected infectious diseases in sub Saharan Africa, and most of the available data is based on blood donors. Health care workers (HCWs) often get infected as a result of their close contact with patients. A cross-sectional study was conducted to determine the prevalence of hepatitis B and C among this group of professionals with a view to improving the quality of care to their patients. Hepatitis B and C infections pose a major public health problem worldwide. While infection is highest in the developing world particularly Asia and sub-Saharan Africa, healthcare workers are at higher risk of acquiring blood-borne viral infections, particularly Hepatitis B and C which are mostly asymptomatic. This study was aimed at determining the prevalence of Hepatitis B and C infections and associated risk factors among health care workers in Dutse Metropolis, Jigawa State - Nigeria. A standard rapid immuno-chromatographic technique i.e. rapid ELISA was used to screen all sera for Hepatitis B surface antigen (HBsAg) and Hepatitis C viral antibody (HCVAb) respectively. Strips containing coated antibodies and antigens to HBV and HCV respectively were removed from the foil. Strips were labeled according to samples. Using a separate disposable pipette, 2 drops of the sample (plasma) were added into each test strip and allowed to run across the absorbent pad. Results were read after 15 minutes. The prevalence of HBV and HCV infection in 100 healthcare workers was determined by testing the plasma collected from the clients during their normal checkup using HBsAg and HCVAb test strips. Results were subjected to statistical analysis using chi-square test. The prevalence of HBV among HCWs was 19 out of 100 (19.0%) and that of HCV was 5 out of 100 (5.0%) where in both cases, higher prevalence was observed among female nurses. It was also observed that all HCV positive cases were recorded among nurses only. The study revealed that nurses are at greater risk of contracting HBV and HCV due to their frequent contact with patients. It is therefore recommended that effective vaccination and other infection control measures be encouraged among healthcare workers. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=prevalence" title="prevalence">prevalence</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis" title=" hepatitis"> hepatitis</a>, <a href="https://publications.waset.org/abstracts/search?q=viruses" title=" viruses"> viruses</a>, <a href="https://publications.waset.org/abstracts/search?q=healthcare%20workers" title=" healthcare workers"> healthcare workers</a>, <a href="https://publications.waset.org/abstracts/search?q=infection" title=" infection"> infection</a> </p> <a href="https://publications.waset.org/abstracts/57533/seroprevalence-of-hepatitis-b-and-c-among-healthcare-workers-in-dutse-metropolis-jigawa-state-nigeria" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/57533.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">360</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6888</span> Bioinformatics Identification of Rare Codon Clusters in Proteins Structure of HBV</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Abdorrasoul%20Malekpour">Abdorrasoul Malekpour</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Ghorbani%20Mojtaba%20Mortazavi"> Mohammad Ghorbani Mojtaba Mortazavi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammadreza%20Fattahi"> Mohammadreza Fattahi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Hassan%20Meshkibaf"> Mohammad Hassan Meshkibaf</a>, <a href="https://publications.waset.org/abstracts/search?q=Ali%20Fakhrzad"> Ali Fakhrzad</a>, <a href="https://publications.waset.org/abstracts/search?q=Saeid%20Salehi"> Saeid Salehi</a>, <a href="https://publications.waset.org/abstracts/search?q=Saeideh%20Zahedi"> Saeideh Zahedi</a>, <a href="https://publications.waset.org/abstracts/search?q=Amir%20Ahmadimoghaddam"> Amir Ahmadimoghaddam</a>, <a href="https://publications.waset.org/abstracts/search?q=Parviz%20Farzadnia%20Dr."> Parviz Farzadnia Dr.</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammadreza%20Hajyani%20Asl%20Bs"> Mohammadreza Hajyani Asl Bs</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis B as an infectious disease has eight main genotypes (A–H). The aim of this study is to Bioinformatically identify Rare Codon Clusters (RCC) in proteins structure of HBV. For detection of protein family accession numbers (Pfam) of HBV proteins; used of uni-prot database and Pfam search tool were used. Obtained Pfam IDs were analyzed in Sherlocc program and RCCs in HBV proteins were detected. In further, the structures of TrEMBL entries proteins studied in PDB database and 3D structures of the HBV proteins and locations of RCCs were visualized and studied using Swiss PDB Viewer software. Pfam search tool have found nine significant hits and 0 insignificant hits in 3 frames. Results of Pfams studied in the Sherlocc program show this program not identified RCCs in the external core antigen (PF08290) and truncated HBeAg protein (PF08290). By contrast the RCCs become identified in Hepatitis core antigen (PF00906) Large envelope protein S (PF00695), X protein (PF00739), DNA polymerase (viral) N-terminal domain (PF00242) and Protein P (Pf00336). In HBV genome, seven RCC identified that found in hepatitis core antigen, large envelope protein S and DNA polymerase proteins and proteins structures of TrEMBL entries sequences that reported in Sherlocc program outputs are not complete. Based on situation of RCC in structure of HBV proteins, it suggested those RCCs are important in HBV life cycle. We hoped that this study provide a new and deep perspective in protein research and drug design for treatment of HBV. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=rare%20codon%20clusters" title="rare codon clusters">rare codon clusters</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20virus" title=" hepatitis B virus"> hepatitis B virus</a>, <a href="https://publications.waset.org/abstracts/search?q=bioinformatic%20study" title=" bioinformatic study"> bioinformatic study</a>, <a href="https://publications.waset.org/abstracts/search?q=infectious%20disease" title=" infectious disease "> infectious disease </a> </p> <a href="https://publications.waset.org/abstracts/24687/bioinformatics-identification-of-rare-codon-clusters-in-proteins-structure-of-hbv" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/24687.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">488</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6887</span> Ultrasensitive Hepatitis B Virus Detection in Blood Using Nano-Porous Silicon Oxide: Towards POC Diagnostics </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=N.%20Das">N. Das</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20Samanta"> N. Samanta</a>, <a href="https://publications.waset.org/abstracts/search?q=L.%20Pandey"> L. Pandey</a>, <a href="https://publications.waset.org/abstracts/search?q=C.%20Roy%20Chaudhuri"> C. Roy Chaudhuri</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Early diagnosis of infection like Hep-B virus in blood is important for low cost medical treatment. For this purpose, it is desirable to develop a point of care device which should be able to detect trace quantities of the target molecule in blood. In this paper, we report a nanoporous silicon oxide sensor which is capable of detecting down to 1fM concentration of Hep-B surface antigen in blood without the requirement of any centrifuge or pre-concentration. This has been made possible by the presence of resonant peak in the sensitivity characteristics. This peak is observed to be dependent only on the concentration of the specific antigen and not on the interfering species in blood serum. The occurrence of opposite impedance change within the pores and at the bottom of the pore is responsible for this effect. An electronic interface has also been designed to provide a display of the virus concentration. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=impedance%20spectroscopy" title="impedance spectroscopy">impedance spectroscopy</a>, <a href="https://publications.waset.org/abstracts/search?q=ultrasensitive%20detection%20in%20blood" title=" ultrasensitive detection in blood"> ultrasensitive detection in blood</a>, <a href="https://publications.waset.org/abstracts/search?q=peak%20frequency" title=" peak frequency"> peak frequency</a>, <a href="https://publications.waset.org/abstracts/search?q=electronic%20interface" title=" electronic interface "> electronic interface </a> </p> <a href="https://publications.waset.org/abstracts/27479/ultrasensitive-hepatitis-b-virus-detection-in-blood-using-nano-porous-silicon-oxide-towards-poc-diagnostics" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/27479.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">401</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6886</span> Developing a Deep Understanding of the Immune Response in Hepatitis B Virus Infected Patients Using a Knowledge Driven Approach</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hanan%20Begali">Hanan Begali</a>, <a href="https://publications.waset.org/abstracts/search?q=Shahi%20Dost"> Shahi Dost</a>, <a href="https://publications.waset.org/abstracts/search?q=Annett%20Ziegler"> Annett Ziegler</a>, <a href="https://publications.waset.org/abstracts/search?q=Markus%20Cornberg"> Markus Cornberg</a>, <a href="https://publications.waset.org/abstracts/search?q=Maria-Esther%20Vidal"> Maria-Esther Vidal</a>, <a href="https://publications.waset.org/abstracts/search?q=Anke%20R.%20M.%20Kraft"> Anke R. M. Kraft</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Chronic hepatitis B virus (HBV) infection can be treated with nucleot(s)ide analog (NA), for example, which inhibits HBV replication. However, they have hardly any influence on the functional cure of HBV, which is defined by hepatitis B surface antigen (HBsAg) loss. NA needs to be taken life-long, which is not available for all patients worldwide. Additionally, NA-treated patients are still at risk of developing cirrhosis, liver failure, or hepatocellular carcinoma (HCC). Although each patient has the same components of the immune system, immune responses vary between patients. Therefore, a deeper understanding of the immune response against HBV in different patients is necessary to understand the parameters leading to HBV cure and to use this knowledge to optimize HBV therapies. This requires seamless integration of an enormous amount of diverse and fine-grained data from viral markers, e.g., hepatitis B core-related antigen (HBcrAg) and hepatitis B surface antigen (HBsAg). The data integration system relies on the assumption that profiling human immune systems requires the analysis of various variables (e.g., demographic data, treatments, pre-existing conditions, immune cell response, or HLA-typing) rather than only one. However, the values of these variables are collected independently. They are presented in a myriad of formats, e.g., excel files, textual descriptions, lab book notes, and images of flow cytometry dot plots. Additionally, patients can be identified differently in these analyses. This heterogeneity complicates the integration of variables, as data management techniques are needed to create a unified view in which individual formats and identifiers are transparent when profiling the human immune systems. The proposed study (HBsRE) aims at integrating heterogeneous data sets of 87 chronically HBV-infected patients, e.g., clinical data, immune cell response, and HLA-typing, with knowledge encoded in biomedical ontologies and open-source databases into a knowledge-driven framework. This new technique enables us to harmonize and standardize heterogeneous datasets in the defined modeling of the data integration system, which will be evaluated in the knowledge graph (KG). KGs are data structures that represent the knowledge and data as factual statements using a graph data model. Finally, the analytic data model will be applied on top of KG in order to develop a deeper understanding of the immune profiles among various patients and to evaluate factors playing a role in a holistic profile of patients with HBsAg level loss. Additionally, our objective is to utilize this unified approach to stratify patients for new effective treatments. This study is developed in the context of the project “Transforming big data into knowledge: for deep immune profiling in vaccination, infectious diseases, and transplantation (ImProVIT)”, which is a multidisciplinary team composed of computer scientists, infection biologists, and immunologists. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B%20infection" title="chronic hepatitis B infection">chronic hepatitis B infection</a>, <a href="https://publications.waset.org/abstracts/search?q=immune%20response" title=" immune response"> immune response</a>, <a href="https://publications.waset.org/abstracts/search?q=knowledge%20graphs" title=" knowledge graphs"> knowledge graphs</a>, <a href="https://publications.waset.org/abstracts/search?q=ontology" title=" ontology"> ontology</a> </p> <a href="https://publications.waset.org/abstracts/153888/developing-a-deep-understanding-of-the-immune-response-in-hepatitis-b-virus-infected-patients-using-a-knowledge-driven-approach" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/153888.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">108</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6885</span> Separation and Characterization of Micobacterium bovis Cell Surface Lysate Antigen</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Albina%20V.%20Moskvicheva">Albina V. Moskvicheva</a>, <a href="https://publications.waset.org/abstracts/search?q=Gevorg%20G.%20Kazarian"> Gevorg G. Kazarian</a>, <a href="https://publications.waset.org/abstracts/search?q=Anna%20R.%20Valeeva"> Anna R. Valeeva</a>, <a href="https://publications.waset.org/abstracts/search?q=Marina%20A.%20Efimova"> Marina A. Efimova</a>, <a href="https://publications.waset.org/abstracts/search?q=Malik%20N.%20Mukminov"> Malik N. Mukminov</a>, <a href="https://publications.waset.org/abstracts/search?q=Eduard%20A.%20Shuralev"> Eduard A. Shuralev</a>, <a href="https://publications.waset.org/abstracts/search?q=Rustam%20Kh.%20Ravilov"> Rustam Kh. Ravilov</a>, <a href="https://publications.waset.org/abstracts/search?q=Kamil%20S.%20Khaertynov"> Kamil S. Khaertynov</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Improving the early diagnosis of tuberculosis and solving a number of problems associated with the differential diagnosis of Mycobacterium bovis infection, nonspecific tuberculin reactions caused by sensitization of the body by non-tuberculosis mycobacteria, is urgent. The filtrates and extracts of M. bovis cell surface components are promising antigens with diagnostic potential. The purpose of this study was to isolate and characterize antigenic proteins and determine the dominant M. bovis antigens recognized by the humoral immune system. The mycobacterial cells were homogenized on FastPrep-24. Gel-filtration chromatography was used to fractionate the lysates of cell surface component extracts and proteins isolated from M. bovis culture supernatant. The separated fractions were analyzed using two-dimensional gel electrophoresis followed by determination of antigen serological activity using immunoblot with specific hyperimmune rabbit blood serum. As a result of electrophoretic separation of components by molecular weight, 23 antigen fractions were obtained. Analysis of densitograms showed that the fractions contained two zones of antigens with pronounced serological activity, corresponding to molecular weights of 28 and 21 kDa. The high serological activity of the 28 kDa antigen was established by immunoblot using hyperimmune blood sera. Separated and characterized by M. bovis specific antigen with a molecular weight of 28 kDa was added to the collection of specific marker antigens for M. bovis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=antigen" title="antigen">antigen</a>, <a href="https://publications.waset.org/abstracts/search?q=gel-filtration%20chromatography" title=" gel-filtration chromatography"> gel-filtration chromatography</a>, <a href="https://publications.waset.org/abstracts/search?q=immunoblot" title=" immunoblot"> immunoblot</a>, <a href="https://publications.waset.org/abstracts/search?q=Mycobacterium%20bovis" title=" Mycobacterium bovis"> Mycobacterium bovis</a> </p> <a href="https://publications.waset.org/abstracts/133644/separation-and-characterization-of-micobacterium-bovis-cell-surface-lysate-antigen" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/133644.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">136</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6884</span> Hepatitis B Vaccination Status and Its Determinants among Primary Health Care Workers in Northwest Pakistan</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Tahir%20Yousafzai">Mohammad Tahir Yousafzai</a>, <a href="https://publications.waset.org/abstracts/search?q=Rubina%20Qasim"> Rubina Qasim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> We assessed Hepatitis B vaccination and its determinants among health care workers (HCW) in Northwest Pakistan. HCWs from both public and private clinics were interviewed about hepatitis B vaccination, socio-demographic, hepatitis B virus transmission modes, disease threat and benefits of vaccination. Logistic regression was performed. Hepatitis B vaccination was 40% (Qualified Physicians: 86% and non-qualified Dispensers:16%). Being Qualified Physician (Adj. OR 26.6; 95%CI 9.3-73.2), Non-qualified Physician (Adj.OR 1.9; 95%CI 0.8-4.6), qualified Dispensers (Adj. OR 3.6; 95%CI 1.3-9.5) compared to non-qualified Dispensers, working in public clinics (Adj. OR 2.5; 95%CI 1.1-5.7) compared to private, perceived disease threat after exposure to blood and body fluids (Adj. OR 1.1; 95%CI 1.1-1.2) and perceived benefits of vaccination (Adj. OR 1.1; 95%CI 1.1-1.2) were significant predictors of hepatitis B vaccination. Improved perception of disease threat and benefits of vaccination and qualification of HCWs are associated with hepatitis B vaccination. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20B%20vaccine" title="Hepatitis B vaccine">Hepatitis B vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=immunization" title=" immunization"> immunization</a>, <a href="https://publications.waset.org/abstracts/search?q=healthcare%20workers" title=" healthcare workers"> healthcare workers</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20health" title=" primary health "> primary health </a> </p> <a href="https://publications.waset.org/abstracts/13926/hepatitis-b-vaccination-status-and-its-determinants-among-primary-health-care-workers-in-northwest-pakistan" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/13926.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">315</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6883</span> Studies of Single Nucleotide Polymorphism of Proteosomal Gene Complex and Their Association with HBV Infection Risk in India</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Jasbir%20Singh">Jasbir Singh</a>, <a href="https://publications.waset.org/abstracts/search?q=Devender%20Kumar"> Devender Kumar</a>, <a href="https://publications.waset.org/abstracts/search?q=Davender%20Redhu"> Davender Redhu</a>, <a href="https://publications.waset.org/abstracts/search?q=Surender%20Kumar"> Surender Kumar</a>, <a href="https://publications.waset.org/abstracts/search?q=Vandana%20Bhardwaj"> Vandana Bhardwaj</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Single Nucleotide polymorphism (SNP) of proteosomal gene complex is involved in the pathogenesis of hepatitis B Virus (HBV) infection. Some of such proteosomal gene complex are large multifunctional proteins (LMP) and antigen associated transporters that help in antigen presentation. Both are involved in intracellular processing and presentation of viral antigens in association with Major Histocompatability Complex (MHC) Class I molecules. A total of hundred each of hepatitis B virus infected and control samples from northern India were studied. Genomic DNA was extracted from all studied samples and PCR-RFLP method was used for genotyping at different positions of LMP genes. Genotypes at a given position were inferred from the pattern of bands and genotype frequencies and haplotype frequencies were also calculated. Homozygous SNP {A>C} was observed at codon 145 of LMP7 gene and having a protective role against HBV as there was statistically significant high distribution of this SNP among controls than cases. Heterozygous SNP {A>C} was observed at codon 145 of LMP7 gene and made individuals more susceptible to HBV infection as there was statistically significant high distribution of this SNP among cases than control. SNP {T>C} was observed at codon 60 of LMP2 gene but statistically significant differences were not observed among controls and cases. For codon 145 of LMP7 and codon 60 of LMP2 genes, four haplotypes were constructed. Haplotype I (LMP2 ‘C’ and LMP7 ‘A’) made individuals carrying it more susceptible to HBV infection as there was statistically significant high distribution of this haplotype among cases than control. Haplotype II (LMP2 ‘C’ and LMP7 ‘C’) made individuals carrying it more immune to HBV infection as there was statistically significant high distribution of this haplotype among control than cases. Thus it can be concluded that homozygous SNP {A>C} at codon 145 of LMP7 and Haplotype II (LMP2 ‘C’ and LMP7 ‘C’) has a protective role against HBV infection whereas heterozygous SNP {A>C} at codon 145 of LMP7 and Haplotype I (LMP2 ‘C’ and LMP7 ‘A’) made individuals more susceptible to HBV infection. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20B%20Virus" title="Hepatitis B Virus">Hepatitis B Virus</a>, <a href="https://publications.waset.org/abstracts/search?q=single%20nucleotide%20polymorphism" title=" single nucleotide polymorphism"> single nucleotide polymorphism</a>, <a href="https://publications.waset.org/abstracts/search?q=low%20molecular%20weight%20proteins" title=" low molecular weight proteins"> low molecular weight proteins</a>, <a href="https://publications.waset.org/abstracts/search?q=transporters%20associated%20with%20antigen%20presentation" title=" transporters associated with antigen presentation"> transporters associated with antigen presentation</a> </p> <a href="https://publications.waset.org/abstracts/60533/studies-of-single-nucleotide-polymorphism-of-proteosomal-gene-complex-and-their-association-with-hbv-infection-risk-in-india" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/60533.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">308</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6882</span> Uptake of Hepatitis B Vaccine among Hepatitis C Positive Patients and Their Vaccine Response in Myanmar</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Zaw%20Z%20Aung">Zaw Z Aung</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: High-risk groups for hepatitis B infection (HBV) are people who injected drugs (PWID), men who have sex with men (MSM), people living with HIV (PLHIV) and persons with hepatitis C (HCV), etc. HBV/HCV coinfected patients are at increased risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma. To the best of author’s knowledge, there is currently no data for hepatitis B vaccine utilization in HCV positive patients and their antibody response. Methodology: From February 2018 to May 2018, consented participants at or above 18 years who came to the clinic in Mandalay were tested with the anti-HCV rapid test. Those who tested HCV positive (n=168) were further tested with hepatitis B profile and asked about their previous hepatitis B vaccination history and risk factors. Results: Out of 168 HCV positive participants, three were excluded for active HBV infections. The remaining 165 were categorized into previously vaccinated 64% (n=106) and unvaccinated 36% (n=59) There were three characteristics groups- PWID monoinfected (n=77), General Population (GP) monoinfected (n=22) and HIV/HCV coinfected participants (n=66). Unvaccinated participants were highest in HIV/HCV, with 68%(n=45) followed by GP (23%, n=5) and PWID (12%, n=9). Among previously vaccinated participants, the highest percentage was PWID (88%, n=68), the second highest was GP (77%, n=17) and lowest in HIV/HCV patients (32%, n=21). 63 participants completed third doses of vaccination (PWID=36, GP=13, HIV/HCV=14). 53% of participants who completed 3 dose of hepatitis B were non-responders (n=34): HIV/HCV (86%, n=12), PWID (44%, n=16), and GP (46%, n=6) Conclusion: Even in the presence of effective and safe hepatitis B vaccine, uptake is low among high risk groups especially PLHIV that needs to be improved. Integration or collaboration of hepatitis B vaccination program, HIV/AIDS and hepatitis C treatment centers is desirable. About half of vaccinated participants were non-responders so that optimal doses, schedule and follow-up testing need to be addressed carefully for those groups. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20B%20vaccine" title="Hepatitis B vaccine">Hepatitis B vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C" title=" Hepatitis C"> Hepatitis C</a>, <a href="https://publications.waset.org/abstracts/search?q=HIV" title=" HIV"> HIV</a>, <a href="https://publications.waset.org/abstracts/search?q=Myanmar" title=" Myanmar"> Myanmar</a> </p> <a href="https://publications.waset.org/abstracts/97724/uptake-of-hepatitis-b-vaccine-among-hepatitis-c-positive-patients-and-their-vaccine-response-in-myanmar" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/97724.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">145</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6881</span> Molecular Evolutionary Relationships Between O-Antigens of Enteric Bacteria</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yuriy%20A.%20Knirel">Yuriy A. Knirel</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Enteric bacteria Escherichia coli is the predominant facultative anaerobe of the colonic flora, and some specific serotypes are associated with enteritis, hemorrhagic colitis, and hemolytic uremic syndrome. Shigella spp. are human pathogens that cause diarrhea and bacillary dysentery (shigellosis). They are in effect E. coli with a specific mode of pathogenicity. Strains of Salmonella enterica are responsible for a food-borne infection (salmonellosis), and specific serotypes cause typhoid fever and paratyphoid fever. All these bacteria are closely related in respect to structure and genetics of the lipopolysaccharide, including the O-polysaccharide part (O‑antigen). Being exposed to the bacterial cell surface, the O antigen is subject to intense selection by the host immune system and bacteriophages giving rise to diverse O‑antigen forms and providing the basis for typing of bacteria. The O-antigen forms of many bacteria are unique, but some are structurally and genetically related to others. The sequenced O-antigen gene clusters between conserved galF and gnd genes were analyzed taking into account the O-antigen structures established by us and others for all S. enterica and Shigella and most E. coli O-serogroups. Multiple genetic mechanisms of diversification of the O-antigen forms, such as lateral gene transfer and mutations, were elucidated and are summarized in the present paper. They include acquisition or inactivation of genes for sugar synthesis or transfer or recombination of O-antigen gene clusters or their parts. The data obtained contribute to our understanding of the origins of the O‑antigen diversity, shed light on molecular evolutionary relationships between the O-antigens of enteric bacteria, and open a way for studies of the role of gene polymorphism in pathogenicity. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=enteric%20bacteria" title="enteric bacteria">enteric bacteria</a>, <a href="https://publications.waset.org/abstracts/search?q=O-antigen%20gene%20cluster" title=" O-antigen gene cluster"> O-antigen gene cluster</a>, <a href="https://publications.waset.org/abstracts/search?q=polysaccharide%20biosynthesis" title=" polysaccharide biosynthesis"> polysaccharide biosynthesis</a>, <a href="https://publications.waset.org/abstracts/search?q=polysaccharide%20structure" title=" polysaccharide structure"> polysaccharide structure</a> </p> <a href="https://publications.waset.org/abstracts/93781/molecular-evolutionary-relationships-between-o-antigens-of-enteric-bacteria" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/93781.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">142</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6880</span> Effects of an Educational Program on Nurses Knowledge and Practice Related to Hepatitis-B: Pre-Experimental Design</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=R.%20S.%20Mehta">R. S. Mehta</a>, <a href="https://publications.waset.org/abstracts/search?q=G.%20N.%20Mandal"> G. N. Mandal </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis-B is the major infectious disease of mankind. In Nepal it is reported that more than 4.3% of Nepalese population at any time in their life has been infected with Hepatitis-B virus (HBV). The objective of this study was to evaluate the effectiveness of planned educational programme regarding knowledge and practice of hepatitis-B among the nurses working at medical units of BPKIHS. Pre-experimental research design was used to conduct the study among the nurses working in medical units of BPKIHS. Total 40 nurses were included in the pre-test and 34 in the post-test. The education intervention was arranged on 24th May 2012 from 2:15 pm to 4:45 pm i.e. two and half hours. After two weeks of education intervention post-test was conducted. Most of the participants (60%) were of the age group of 18-22 years, Hindu (82.5%), and unmarried (65%). After education intervention there is significant differences in knowledge on the components of Hepatitis-B at 0.05 level of significance. There is no difference in the attitude components after post-test except the component patient contaminated with Hepatitis-B must be called as the last patient (p=0.035). It can conclude that hepatitis-B educational program improved knowledge and practice among the nurses. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=educational%20program" title="educational program">educational program</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis-B" title=" Hepatitis-B"> Hepatitis-B</a>, <a href="https://publications.waset.org/abstracts/search?q=pre-experimental%20design" title=" pre-experimental design"> pre-experimental design</a>, <a href="https://publications.waset.org/abstracts/search?q=medical%20units" title=" medical units "> medical units </a> </p> <a href="https://publications.waset.org/abstracts/16607/effects-of-an-educational-program-on-nurses-knowledge-and-practice-related-to-hepatitis-b-pre-experimental-design" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/16607.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">356</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6879</span> Frequency of Hepatitis C Virus in Diagnosed Tuberculosis Cases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20Farooq%20Baig">Muhammad Farooq Baig</a>, <a href="https://publications.waset.org/abstracts/search?q=Saleem%20Qadeer"> Saleem Qadeer</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The frequency of hepatitis C virus infection along with tuberculosis has not been widely investigated and very low statistics on rates of hepatitis C virus co-infection in tuberculosis patients. Hepatotoxicity is the major side effect of anti-tuberculosis therapy hepatitis HCVliver disease elevates the chances of hepatotoxicity up-to five folds. Objectives & Aim: To see the frequency of Hepatitis Cvirus infection amongst people with diagnosed Tuberculosis using gene X-pert technique. To evaluate the factors associated with HCVinfection in patients with MTBtuberculosis and to determine sensitivity and specificity of the tests. Study design: Comparative analytical study. Methodology: Three hundred and thirteen patients of tuberculosis diagnosed by Genexpert included while testing hepatitis C virus using immunochromotography rapid test technique, enzyme linked immunosorbent assay method and polymerase chain reaction test for confirmation. Results:Higher frequency of tuberculosis infection in males 57.8%, 42.5% between 20-39 years and 22% of hepatitis C virus infection in tuberculosis patients.The sensitivity of rapid test and enzyme-linked immunosorbent assay was 79% and 96% respectively while the specificity of rapid test and enzyme-linked immunosorbent assay was 91% and 99% respectively. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mycobactrium%20Tuberculosis" title="Mycobactrium Tuberculosis">Mycobactrium Tuberculosis</a>, <a href="https://publications.waset.org/abstracts/search?q=PC%27R" title=" PC'R"> PC'R</a>, <a href="https://publications.waset.org/abstracts/search?q=Gene%20x%20pert" title=" Gene x pert"> Gene x pert</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C%20virus" title=" Hepatitis C virus"> Hepatitis C virus</a> </p> <a href="https://publications.waset.org/abstracts/170292/frequency-of-hepatitis-c-virus-in-diagnosed-tuberculosis-cases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/170292.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">76</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6878</span> Lentiviral-Based Novel Bicistronic Therapeutic Vaccine against Chronic Hepatitis B Induces Robust Immune Response</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohamad%20F.%20Jamiluddin">Mohamad F. Jamiluddin</a>, <a href="https://publications.waset.org/abstracts/search?q=Emeline%20Sarry"> Emeline Sarry</a>, <a href="https://publications.waset.org/abstracts/search?q=Ana%20Bejanariu"> Ana Bejanariu</a>, <a href="https://publications.waset.org/abstracts/search?q=C%C3%A9cile%20Bauche"> Cécile Bauche </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Over 360 million people are chronically infected with hepatitis B virus (HBV), of whom 1 million die each year from HBV-associated liver cirrhosis or hepatocellular carcinoma. Current treatment options for chronic hepatitis B depend on interferon-α (IFNα) or nucleos(t)ide analogs, which control virus replication but rarely eliminate the virus. Treatment with PEG-IFNα leads to a sustained antiviral response in only one third of patients. After withdrawal of the drugs, the rebound of viremia is observed in the majority of patients. Furthermore, the long-term treatment is subsequently associated with the appearance of drug resistant HBV strains that is often the cause of the therapy failure. Among the new therapeutic avenues being developed, therapeutic vaccine aimed at inducing immune responses similar to those found in resolvers is of growing interest. The high prevalence of chronic hepatitis B necessitates the design of better vaccination strategies capable of eliciting broad-spectrum of cell-mediated immunity(CMI) and humoral immune response that can control chronic hepatitis B. Induction of HBV-specific T cells and B cells by therapeutic vaccination may be an innovative strategy to overcome virus persistence. Lentiviral vectors developed and optimized by THERAVECTYS, due to their ability to transduce non-dividing cells, including dendritic cells, and induce CMI response, have demonstrated their effectiveness as vaccination tools. Method: To develop a HBV therapeutic vaccine that can induce a broad but specific immune response, we generated recombinant lentiviral vector carrying IRES(Internal Ribosome Entry Site)-containing bicistronic constructs which allow the coexpression of two vaccine products, namely HBV T- cell epitope vaccine and HBV virus like particle (VLP) vaccine. HBV T-cell epitope vaccine consists of immunodominant cluster of CD4 and CD8 epitopes with spacer in between them and epitopes are derived from HBV surface protein, HBV core, HBV X and polymerase. While HBV VLP vaccine is a HBV core protein based chimeric VLP with surface protein B-cell epitopes displayed. In order to evaluate the immunogenicity, mice were immunized with lentiviral constructs by intramuscular injection. The T cell and antibody immune responses of the two vaccine products were analyzed using IFN-γ ELISpot assay and ELISA respectively to quantify the adaptive response to HBV antigens. Results: Following a single administration in mice, lentiviral construct elicited robust antigen-specific IFN-γ responses to the encoded antigens. The HBV T- cell epitope vaccine demonstrated significantly higher T cell immunogenicity than HBV VLP vaccine. Importantly, we demonstrated by ELISA that antibodies are induced against both HBV surface protein and HBV core protein when mice injected with vaccine construct (p < 0.05). Conclusion: Our results highlight that THERAVECTYS lentiviral vectors may represent a powerful platform for immunization strategy against chronic hepatitis B. Our data suggests the likely importance of Lentiviral vector based novel bicistronic construct for further study, in combination with drugs or as standalone antigens, as a therapeutic lentiviral based HBV vaccines. THERAVECTYS bicistronic HBV vaccine will be further evaluated in animal efficacy studies. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B" title="chronic hepatitis B">chronic hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=lentiviral%20vectors" title=" lentiviral vectors"> lentiviral vectors</a>, <a href="https://publications.waset.org/abstracts/search?q=therapeutic%20vaccine" title=" therapeutic vaccine"> therapeutic vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=virus-like%20particle" title=" virus-like particle"> virus-like particle</a> </p> <a href="https://publications.waset.org/abstracts/34143/lentiviral-based-novel-bicistronic-therapeutic-vaccine-against-chronic-hepatitis-b-induces-robust-immune-response" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34143.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">334</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6877</span> Multicenter Evaluation of the ACCESS HBsAg and ACCESS HBsAg Confirmatory Assays on the DxI 9000 ACCESS Immunoassay Analyzer, for the Detection of Hepatitis B Surface Antigen</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Vanessa%20Roulet">Vanessa Roulet</a>, <a href="https://publications.waset.org/abstracts/search?q=Marc%20Turini"> Marc Turini</a>, <a href="https://publications.waset.org/abstracts/search?q=Juliane%20Hey"> Juliane Hey</a>, <a href="https://publications.waset.org/abstracts/search?q=St%C3%A9phanie%20Bord-Romeu"> Stéphanie Bord-Romeu</a>, <a href="https://publications.waset.org/abstracts/search?q=Emilie%20Bonzom"> Emilie Bonzom</a>, <a href="https://publications.waset.org/abstracts/search?q=Mahmoud%20Badawi"> Mahmoud Badawi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammed-Amine%20Chakir"> Mohammed-Amine Chakir</a>, <a href="https://publications.waset.org/abstracts/search?q=Val%C3%A9rie%20Simon"> Valérie Simon</a>, <a href="https://publications.waset.org/abstracts/search?q=Vanessa%20Viotti"> Vanessa Viotti</a>, <a href="https://publications.waset.org/abstracts/search?q=J%C3%A9r%C3%A9mie%20Gautier"> Jérémie Gautier</a>, <a href="https://publications.waset.org/abstracts/search?q=Fran%C3%A7oise%20Le%20Boulaire"> Françoise Le Boulaire</a>, <a href="https://publications.waset.org/abstracts/search?q=Catherine%20Coignard"> Catherine Coignard</a>, <a href="https://publications.waset.org/abstracts/search?q=Claire%20Vincent"> Claire Vincent</a>, <a href="https://publications.waset.org/abstracts/search?q=Sandrine%20Greaume"> Sandrine Greaume</a>, <a href="https://publications.waset.org/abstracts/search?q=Isabelle%20Voisin"> Isabelle Voisin</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Beckman Coulter, Inc. has recently developed fully automated assays for the detection of HBsAg on a new immunoassay platform. The objective of this European multicenter study was to evaluate the performance of the ACCESS HBsAg and ACCESS HBsAg Confirmatory assays† on the recently CE-marked DxI 9000 ACCESS Immunoassay Analyzer. Methods: The clinical specificity of the ACCESS HBsAg and HBsAg Confirmatory assays was determined using HBsAg-negative samples from blood donors and hospitalized patients. The clinical sensitivity was determined using presumed HBsAg-positive samples. Sample HBsAg status was determined using a CE-marked HBsAg assay (Abbott ARCHITECT HBsAg Qualitative II, Roche Elecsys HBsAg II, or Abbott PRISM HBsAg assay) and a CE-marked HBsAg confirmatory assay (Abbott ARCHITECT HBsAg Qualitative II Confirmatory or Abbott PRISM HBsAg Confirmatory assay) according to manufacturer package inserts and pre-determined testing algorithms. False initial reactive rate was determined on fresh hospitalized patient samples. The sensitivity for the early detection of HBV infection was assessed internally on thirty (30) seroconversion panels. Results: Clinical specificity was 99.95% (95% CI, 99.86 – 99.99%) on 6047 blood donors and 99.71% (95%CI, 99.15 – 99.94%) on 1023 hospitalized patient samples. A total of six (6) samples were found false positive with the ACCESS HBsAg assay. None were confirmed for the presence of HBsAg with the ACCESS HBsAg Confirmatory assay. Clinical sensitivity on 455 HBsAg-positive samples was 100.00% (95% CI, 99.19 – 100.00%) for the ACCESS HBsAg assay alone and for the ACCESS HBsAg Confirmatory assay. The false initial reactive rate on 821 fresh hospitalized patient samples was 0.24% (95% CI, 0.03 – 0.87%). Results obtained on 30 seroconversion panels demonstrated that the ACCESS HBsAg assay had equivalent sensitivity performances compared to the Abbott ARCHITECT HBsAg Qualitative II assay with an average bleed difference since first reactive bleed of 0.13. All bleeds found reactive in ACCESS HBsAg assay were confirmed in ACCESS HBsAg Confirmatory assay. Conclusion: The newly developed ACCESS HBsAg and ACCESS HBsAg Confirmatory assays from Beckman Coulter have demonstrated high clinical sensitivity and specificity, equivalent to currently marketed HBsAg assays, as well as a low false initial reactive rate. †Pending achievement of CE compliance; not yet available for in vitro diagnostic use. 2023-11317 Beckman Coulter and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=dxi%209000%20access%20immunoassay%20analyzer" title="dxi 9000 access immunoassay analyzer">dxi 9000 access immunoassay analyzer</a>, <a href="https://publications.waset.org/abstracts/search?q=hbsag" title=" hbsag"> hbsag</a>, <a href="https://publications.waset.org/abstracts/search?q=hbv" title=" hbv"> hbv</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20b%20surface%20antigen" title=" hepatitis b surface antigen"> hepatitis b surface antigen</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20b%20virus" title=" hepatitis b virus"> hepatitis b virus</a>, <a href="https://publications.waset.org/abstracts/search?q=immunoassay" title=" immunoassay"> immunoassay</a> </p> <a href="https://publications.waset.org/abstracts/164572/multicenter-evaluation-of-the-access-hbsag-and-access-hbsag-confirmatory-assays-on-the-dxi-9000-access-immunoassay-analyzer-for-the-detection-of-hepatitis-b-surface-antigen" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/164572.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">90</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6876</span> Dynamic Modelling of Hepatitis B Patient Using Sihar Model</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Alakija%20Temitope%20Olufunmilayo">Alakija Temitope Olufunmilayo</a>, <a href="https://publications.waset.org/abstracts/search?q=Akinyemi"> Akinyemi</a>, <a href="https://publications.waset.org/abstracts/search?q=Yagba%20Joy"> Yagba Joy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis is the inflammation of the liver tissue that can cause whiteness of the eyes (Jaundice), lack of appetite, vomiting, tiredness, abdominal pain, diarrhea. Hepatitis is acute if it resolves within 6 months and chronic if it last longer than 6 months. Acute hepatitis can resolve on its own, lead to chronic hepatitis or rarely result in acute liver failure. Chronic hepatitis may lead to scarring of the liver (Cirrhosis), liver failure and liver cancer. Modelling Hepatitis B may become necessary in order to reduce its spread. So, dynamic SIR model can be used. This model consists of a system of three coupled non-linear ordinary differential equation which does not have an explicit formula solution. It is an epidemiological model used to predict the dynamics of infectious disease by categorizing the population into three possible compartments. In this study, a five-compartment dynamic model of Hepatitis B disease was proposed and developed by adding control measure of sensitizing the public called awareness. All the mathematical and statistical formulation of the model, especially the general equilibrium of the model, was derived, including the nonlinear least square estimators. The initial parameters of the model were derived using nonlinear least square embedded in R code. The result study shows that the proportion of Hepatitis B patient in the study population is 1.4 per 1,000,000 populations. The estimated Hepatitis B induced death rate is 0.0108, meaning that 1.08% of the infected individuals die of the disease. The reproduction number of Hepatitis B diseases in Nigeria is 6.0, meaning that one individual can infect more than 6.0 people. The effect of sensitizing the public on the basic reproduction number is significant as the reproduction number is reduced. The study therefore recommends that programme should be designed by government and non-governmental organization to sensitize the entire Nigeria population in order to reduce cases of Hepatitis B disease among the citizens. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B" title="hepatitis B">hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=modelling" title=" modelling"> modelling</a>, <a href="https://publications.waset.org/abstracts/search?q=non-linear%20ordinary%20differential%20equation" title=" non-linear ordinary differential equation"> non-linear ordinary differential equation</a>, <a href="https://publications.waset.org/abstracts/search?q=sihar%20model" title=" sihar model"> sihar model</a>, <a href="https://publications.waset.org/abstracts/search?q=sensitization" title=" sensitization"> sensitization</a> </p> <a href="https://publications.waset.org/abstracts/171002/dynamic-modelling-of-hepatitis-b-patient-using-sihar-model" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/171002.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">89</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6875</span> Development of Cationic Gelatin Nanoparticles as an Antigen-Carrier for Mucosal Immunization</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ping-Lun%20Jiang">Ping-Lun Jiang</a>, <a href="https://publications.waset.org/abstracts/search?q=Hung-Jun%20Lin"> Hung-Jun Lin</a>, <a href="https://publications.waset.org/abstracts/search?q=Shen-Fu%20Lin"> Shen-Fu Lin</a>, <a href="https://publications.waset.org/abstracts/search?q=Mei-Yin%20Chien"> Mei-Yin Chien</a>, <a href="https://publications.waset.org/abstracts/search?q=Ting-Wei%20Li"> Ting-Wei Li</a>, <a href="https://publications.waset.org/abstracts/search?q=Chun-Han%20Lin"> Chun-Han Lin</a>, <a href="https://publications.waset.org/abstracts/search?q=Der-Zen%20Liu"> Der-Zen Liu</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Mucosal vaccine induces both mucosal (secretory IgA) and systemic immune responses and it is considered an ideal vaccination strategy for prevention of infectious diseases. One important point to be considered in mucosal vaccination is effective antigen delivery system which can manage effective delivery of antigen to antigen-presenting cells (APCs) of mucosal. In the present study, cationic gelatin nanoparticles were prepared as ideal carriers for more efficient antigen delivery. The average diameter of cationic gelatin nanoparticle was approximate 190 nm, and the zeta potential was about +45 mV, then ovalbumin (OVA) was physically absorbed onto cationic gelatin nanoparticle. The OVA absorption rate was near 95% the zeta potential was about +20 mV. We show that cationic gelatin nanoparticle effectively facilitated antigen uptake by mice bone marrow-derived dendritic cells (mBMDCs) and RAW264.7 cells and induced higher levels of pro-inflammatory cytokines. C57BL/6 mice twice immunized intranasally with OVA-absorbed cationic gelatin nanoparticle induced high levels of OVA-specific IgG in the serum and IgA in their in the nasal and lung wash fluid. These results indicate that nasal administration of cationic gelatin nanoparticles induced both mucosal and systemic immune responses and cationic gelatin nanoparticles might be a potential antigen delivery carrier for further clinical applications. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=antigen%20delivery" title="antigen delivery">antigen delivery</a>, <a href="https://publications.waset.org/abstracts/search?q=antigen-presenting%20cells" title=" antigen-presenting cells"> antigen-presenting cells</a>, <a href="https://publications.waset.org/abstracts/search?q=gelatin%20nanoparticle" title=" gelatin nanoparticle"> gelatin nanoparticle</a>, <a href="https://publications.waset.org/abstracts/search?q=mucosal%20vaccine" title=" mucosal vaccine"> mucosal vaccine</a> </p> <a href="https://publications.waset.org/abstracts/42981/development-of-cationic-gelatin-nanoparticles-as-an-antigen-carrier-for-mucosal-immunization" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/42981.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">359</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6874</span> A Medical Resource Forecasting Model for Emergency Room Patients with Acute Hepatitis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=R.%20J.%20Kuo">R. J. Kuo</a>, <a href="https://publications.waset.org/abstracts/search?q=W.%20C.%20Cheng"> W. C. Cheng</a>, <a href="https://publications.waset.org/abstracts/search?q=W.%20C.%20Lien"> W. C. Lien</a>, <a href="https://publications.waset.org/abstracts/search?q=T.%20J.%20Yang"> T. J. Yang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Taiwan is a hyper endemic area for the Hepatitis B virus (HBV). The estimated total number of HBsAg carriers in the general population who are more than 20 years old is more than 3 million. Therefore, a case record review is conducted from January 2003 to June 2007 for all patients with a diagnosis of acute hepatitis who were admitted to the Emergency Department (ED) of a well-known teaching hospital. The cost for the use of medical resources is defined as the total medical fee. In this study, principal component analysis (PCA) is firstly employed to reduce the number of dimensions. Support vector regression (SVR) and artificial neural network (ANN) are then used to develop the forecasting model. A total of 117 patients meet the inclusion criteria. 61% patients involved in this study are hepatitis B related. The computational result shows that the proposed PCA-SVR model has superior performance than other compared algorithms. In conclusion, the Child-Pugh score and echogram can both be used to predict the cost of medical resources for patients with acute hepatitis in the ED. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acute%20hepatitis" title="acute hepatitis">acute hepatitis</a>, <a href="https://publications.waset.org/abstracts/search?q=medical%20resource%20cost" title=" medical resource cost"> medical resource cost</a>, <a href="https://publications.waset.org/abstracts/search?q=artificial%20neural%20network" title=" artificial neural network"> artificial neural network</a>, <a href="https://publications.waset.org/abstracts/search?q=support%20vector%20regression" title=" support vector regression"> support vector regression</a> </p> <a href="https://publications.waset.org/abstracts/23255/a-medical-resource-forecasting-model-for-emergency-room-patients-with-acute-hepatitis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/23255.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">422</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6873</span> Methylprednisolone Injection Did Not Inhibit Anti-Hbs Response Following Hepatitis B Vaccination in Mice</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=P.%20O.%20Ughachukwu">P. O. Ughachukwu</a>, <a href="https://publications.waset.org/abstracts/search?q=P.%20O.%20Okonkwo"> P. O. Okonkwo</a>, <a href="https://publications.waset.org/abstracts/search?q=P.%20C.%20Unekwe"> P. C. Unekwe</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20O.%20Ogamba"> J. O. Ogamba</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The prevalence of hepatitis B viral infection is high worldwide with liver cirrhosis and hepatocellular carcinoma as important complications. Cases of poor antibody response to hepatitis B vaccination abound. Immunosuppression, especially from glucocorticoids, is often cited as a cause of poor antibody response and there are documented evidences of irrational administration of glucocorticoids to children and adults. The study was, therefore, designed to find out if administration of glucocorticoids affects immune response to vaccination against hepatitis B in mice. Methods: Mice of both sexes were randomly divided into 2 groups. Daily intramuscular methylprednisolone injections, (15 mg kg-1), were given to the test group while sterile deionized water (0.1ml) was given to control mice for 30 days. On day 6 all mice were given 2 μg (0.1ml) hepatitis B vaccine and a booster dose on day 27. On day 34, blood samples were collected and analyzed for anti-HBs titres using enzyme-linked immunosorbent assay (ELISA). Statistical analysis was done using Graph Pad Prism 5.0 and the results taken as statistically significant at p value < 0.05. Results: There were positive serum anti-HBs responses in all mice groups but the differences in titres were not statistically significant. Conclusions: At the dosages and length of exposure used in this study, methylprednisolone injection did not significantly inhibit anti-HBs response in mice following immunization against hepatitis B virus. By extrapolation, methylprednisolone, when used in the usual clinical doses and duration of therapy, is not likely to inhibit immune response to hepatitis B vaccinations in man. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anti-HBs" title="anti-HBs">anti-HBs</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine" title=" hepatitis B vaccine"> hepatitis B vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=immune%20response" title=" immune response"> immune response</a>, <a href="https://publications.waset.org/abstracts/search?q=methylprednisolone" title=" methylprednisolone"> methylprednisolone</a>, <a href="https://publications.waset.org/abstracts/search?q=mice" title=" mice"> mice</a> </p> <a href="https://publications.waset.org/abstracts/28711/methylprednisolone-injection-did-not-inhibit-anti-hbs-response-following-hepatitis-b-vaccination-in-mice" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/28711.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">323</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6872</span> An Investigation of Etiology of Liver Cirrhosis and Its Complications with Other Co-morbid Diseases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tayba%20Akram">Tayba Akram</a> </p> <p class="card-text"><strong>Abstract:</strong></p> our main objective of this study is to work on the etiology of liver cirrhosis, to find basic reasons and causes of liver damage, and to find the pattern of liver cirrhosis in hepatic patients either suffering from hepatitis B/C or simple jaundice. We can evaluate medical treatment and the latest trends in patients suffering from liver cirrhosis. We can evaluate the side effects and adverse effects induced by drug therapy used to treat liver cirrhosis. The conclusion is based on the etiology of liver cirrhosis. The most common cause of liver cirrhosis is the viral Hepatitis C virus. Other common causes of liver cirrhosis that are estimated from our research are Hepatitis B virus, Diabetes Mellitus, Ascites, and very rarely found Hepatitis D virus. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=etiology" title="etiology">etiology</a>, <a href="https://publications.waset.org/abstracts/search?q=liver" title=" liver"> liver</a>, <a href="https://publications.waset.org/abstracts/search?q=cirrhosis" title=" cirrhosis"> cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=co-morbid%20diseases" title=" co-morbid diseases"> co-morbid diseases</a> </p> <a href="https://publications.waset.org/abstracts/193100/an-investigation-of-etiology-of-liver-cirrhosis-and-its-complications-with-other-co-morbid-diseases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/193100.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">12</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6871</span> An In-silico Pharmacophore-Based Anti-Viral Drug Development for Hepatitis C Virus</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Romasa%20Qasim">Romasa Qasim</a>, <a href="https://publications.waset.org/abstracts/search?q=G.%20M.%20Sayedur%20Rahman"> G. M. Sayedur Rahman</a>, <a href="https://publications.waset.org/abstracts/search?q=Nahid%20Hasan"> Nahid Hasan</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Shazzad%20Hosain"> M. Shazzad Hosain</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Millions of people worldwide suffer from Hepatitis C, one of the fatal diseases. Interferon (IFN) and ribavirin are the available treatments for patients with Hepatitis C, but these treatments have their own side-effects. Our research focused on the development of an orally taken small molecule drug targeting the proteins in Hepatitis C Virus (HCV), which has lesser side effects. Our current study aims to the Pharmacophore based drug development of a specific small molecule anti-viral drug for Hepatitis C Virus (HCV). Drug designing using lab experimentation is not only costly but also it takes a lot of time to conduct such experimentation. Instead in this in silico study, we have used computer-aided techniques to propose a Pharmacophore-based anti-viral drug specific for the protein domains of the polyprotein present in the Hepatitis C Virus. This study has used homology modeling and ab initio modeling for protein 3D structure generation followed by pocket identification in the proteins. Drug-able ligands for the pockets were designed using de novo drug design method. For ligand design, pocket geometry is taken into account. Out of several generated ligands, a new Pharmacophore is proposed, specific for each of the protein domains of HCV. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=pharmacophore-based%20drug%20design" title="pharmacophore-based drug design">pharmacophore-based drug design</a>, <a href="https://publications.waset.org/abstracts/search?q=anti-viral%20drug" title=" anti-viral drug"> anti-viral drug</a>, <a href="https://publications.waset.org/abstracts/search?q=in-silico%20drug%20design" title=" in-silico drug design"> in-silico drug design</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C%20virus%20%28HCV%29" title=" Hepatitis C virus (HCV)"> Hepatitis C virus (HCV)</a> </p> <a href="https://publications.waset.org/abstracts/64266/an-in-silico-pharmacophore-based-anti-viral-drug-development-for-hepatitis-c-virus" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/64266.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">271</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6870</span> Prevalence Determination of Hepatitis D Virus Genotypes among HBsAg Positive Patients in Kerman Province of Iran</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Khabat%20Barkhordari">Khabat Barkhordari</a>, <a href="https://publications.waset.org/abstracts/search?q=Ali%20Mohammad%20Arabzadeh"> Ali Mohammad Arabzadeh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis delta virus (HDV) is a RNA virus that needs the function of hepatitis B virus (HBV) for its propagation and assembly. Infection by HDV can occur spontaneously with HBV infection and cause acute hepatitis or develop as secondary infection in HBV suffering patients. Based on genome sequence analysis, HDV has several genotypes which show broad geographic and diverse clinical features. The aim of current study is determine the prevalence of hepatitis delta virus genotype in patients with positive HBsAg in Kerman province of Iran. This cross-sectional study a total of 400 patients with HBV infection attending the clinic center of Besat from 2012 to 2014 were included. We carried out ELISA to detect anti-HDV antibodies. Those testing positive were analyzed further for HDV-RNA and for genotyping using restriction fragment length polymorphism (RFLP) and RT-nested PCR- sequencing. Among 400 patients in this study, 67 cases (16.75 %) were containing anti-HDV antibody which we found HDV RNA in just 7 (1.75%) serum samples. Analysis of these 7 positive HDV showed that all of them have genotype I. According to current study the HDV prevalence in Kerman is higher than the reported prevalence of 6.6% for Iran as a whole and clade 1 (genotype 1) is the predominant clade of HDV in Kerman. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=genotyping" title="genotyping">genotyping</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20delta%20virus" title=" hepatitis delta virus"> hepatitis delta virus</a>, <a href="https://publications.waset.org/abstracts/search?q=molecular%20epidemiology" title=" molecular epidemiology"> molecular epidemiology</a>, <a href="https://publications.waset.org/abstracts/search?q=Kerman" title=" Kerman"> Kerman</a>, <a href="https://publications.waset.org/abstracts/search?q=Iran" title=" Iran"> Iran</a> </p> <a href="https://publications.waset.org/abstracts/36576/prevalence-determination-of-hepatitis-d-virus-genotypes-among-hbsag-positive-patients-in-kerman-province-of-iran" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/36576.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">294</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6869</span> Molecular Epidemiologic Distribution of HDV Genotypes among Different Ethnic Groups in Iran: A Systematic Review</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Khabat%20Barkhordari">Khabat Barkhordari</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis delta virus (HDV) is a RNA virus that needs the function of hepatitis B virus (HBV) for its propagation and assembly. Infection by HDV can occur spontaneously with HBV infection and cause acute hepatitis or develop as secondary infection in HBV suffering patients. Based on genome sequence analysis, HDV has several genotypes which show broad geographic and diverse clinical features. The aim of current study is determine the molecular epidemiology of hepatitis delta virus genotype in patients with positive HBsAg among different ethnic groups of Iran. This systematic review study reviews the results of different studies which examined 2000 Iranian patients with HBV infection from 2010 to 2015. Among 2000 patients in this study, 16.75 % were containing anti-HDV antibody and HDV RNA was found in just 1.75% cases. All of positive cases also have genotype I. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HDV" title="HDV">HDV</a>, <a href="https://publications.waset.org/abstracts/search?q=genotype" title=" genotype"> genotype</a>, <a href="https://publications.waset.org/abstracts/search?q=epidemiology" title=" epidemiology"> epidemiology</a>, <a href="https://publications.waset.org/abstracts/search?q=distribution" title=" distribution "> distribution </a> </p> <a href="https://publications.waset.org/abstracts/37480/molecular-epidemiologic-distribution-of-hdv-genotypes-among-different-ethnic-groups-in-iran-a-systematic-review" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/37480.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">275</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=229">229</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=230">230</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigen&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>